CETP
Cholesteryl ester transfer protein
Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesteryl esters from the atheroprotective high density lipoprotein (HDL) to the proatherogenic low density lipoprotein cholesterol (LDL) and very low density lipoprotein cholesterol (VLDL) leading to lower levels of HDL but raising the levels of proatherogenic LDL and VLDL. CETP inhibitors are a class of drugs that targets the CETP enzyme to significantly increase serum HDL-C and decrease LDL-C levels. Inhibition of CETP is considered a potential approach to treat dyslipidemia.
Alterations of CETP activity levels can be caused by single-base polymorphisms as well as by alternative splicing. Several common variants in CETP have been reported to be associated with variation in plasma lipid levels, CAD risk and/or CETP mass/activity. The rare genetic variants in the CETP gene also contribute to the phenotypic variation of HDL-C in the general population.
All Product Categories
-
CETP Related Products (37)
Related Products (37)
-
Antibodies (1)
- 1
- 2
-
Tiqueside
0 ImagesCat. No.: HY-106106CAS No.: 99759-19-0Synonyms: CP‐88,818; β‐Tigogenin cellobiosideTiqueside (CP‐88,818) is an orally active cholesterol absorption inhibitor. Tiqueside inhibits absorption of both dietary cholesterol and endogenous cholesterol excreted into the intestinal lumen via the bile. Tiqueside can be used in the research of hypercholesterolemia.
-
BI-5756
0 ImagesCat. No.: HY-171883CAS No.: 1332485-18-3BI-5756 is a CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. BI-5756 can significantly increase HDL-C levels and reduce LDL-C levels. BI-5756 can also enhance the function of regulatory T cells while maintaining T cell-mediated anti-tumor activity. BI-5756 can directly inhibit the growth of tumor cells and upregulate the expression of MHC I, MHC II, and CD80 on tumor cells. BI-5756 has a protective effect in graft-versus-host disease models. BI-5756 can be used in research on tumors, graft-versus-host disease, and metabolic diseases.
-
CP-800569
0 ImagesCat. No.: HY-105316CAS No.: 263262-73-3CP-800569 is an orally active cholesteryl ester transfer protein (CETP) inhibitor. CP-800569 can decrease low-density lipoprotein and postprandial triglyceride and increase high-density lipoprotein. CP-800569 can be used for the research of metabolic disease.
-
Canosimibe
0 ImagesCat. No.: HY-19497CAS No.: 768394-99-6Synonyms: AVE-5530; BART-1741Canosimibe is a cholesterol absorption inhibitor extracted from patent WO2004087655A1.
-
BMS-188494
0 ImagesCat. No.: HY-16109CAS No.: 191866-32-7BMS-188494 is a cholesterol-lowering agent that degrades into a monoester form, BMS-188494, and a free acid form, BMS-187745.
-
Colestolone
0 ImagesCat. No.: HY-W414588CAS No.: 50673-97-7Colestolone is a 15-ketosterol compound and an orally active inhibitor of HMG-CoA reductase. Colestolone can inhibit the activity of cholesteryl ester transfer protein (CETP) in vitro (IC50 = 660 μM). Colestolone is a cholesterol-lowering agent, and can be used in the research of endocrine and metabolic diseases such as hyperlipidemia.
-
Monometacrine
0 ImagesMonometacrine is a cholesterol esterase inhibitor. Monometacrine has antidepressant effect.
-
Obicetrapib sodium
0 ImagesCat. No.: HY-18778ACAS No.: 866399-88-4Synonyms: TA-8995 sodium; DEZ-001 sodium; AMG-899 sodiumObicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
-
DRL-17822
0 ImagesCat. No.: HY-182320CAS No.: 898911-09-6DRL-17822 is a selective cholesteryl ester transfer protein (CETP) inhibitor. DRL-17822 increases high-density lipoprotein levels. The exposure of DRL-17822 nanocrystal formulation increases significantly after a high-fat breakfast. The exposure of DRL-17822 in the fasted state is higher than that of its nanocrystal formulation. DRL-17822 can be used in the research of type II hyperlipidemia and atherosclerotic cardiovascular disease.
-
Dalcetrapib (Standard)
0 ImagesSynonyms: JTT-705 (Standard); RO4607381 (Standard)Dalcetrapib (Standard) is the analytical standard of Dalcetrapib. This product is intended for research and analytical applications. Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively.
-
3-Pyridinemethanol (Standard)
0 ImagesSynonyms: Nicotinyl alcohol (Standard); Pyridine-3-carbinol (Standard)3-Pyridinemethanol (Standard) is the analytical standard of 3-Pyridinemethanol. This product is intended for research and analytical applications. 3-Pyridinemethanol (Nicotinyl alcohol), a pyridine derivative, is a cholesterol-lowering agent. 3-Pyridinemethanol can be selectively oxidized to vitamin B3.
-
CETP-IN-4
0 ImagesCat. No.: HY-142643CAS No.: 1648889-70-6CETP-IN-4 is a cholesteryl ester transfer protein (CETP) inhibitor.
-
CP 524515
0 ImagesCat. No.: HY-169723CAS No.: 262352-13-6CP 524515 is a potent inhbitor of cholesteryl ester transfer protein (CETP) that leads to elevated high-density lipoprotein cholesterol levels.
-
Azacosterol dihydrochloride
0 ImagesAzacosterol (SC-12937) dihydrochloride is a chemosterilant which in-hibits reproduction in the pigeon. Azacosterol (SC-12937) dihydrochloride exerts its inhibitory effect through the blocking of the synthesis of cholesterol, thought to be a vital component in the formation of egg yolks.
-
Azalanstat mesylate
0 ImagesCat. No.: HY-105191CCAS No.: 143484-80-4Synonyms: RS-21607 mesylateAzalanstat (RS-21607) mesylate is an orally active lanosterol 14α-demethylase inhibitor. Azalanstat mesylate exerts a cholesterol-lowering effect by inhibiting cholesterol synthesis and regulating HMG-CoA Reductase (HMGCR), and shows an additive effect when used in combination with Cholestyramine (HY-104081). Azalanstat mesylate is used in the study of hypercholesterolemia.
-
Obicetrapib hemicalcium
0 ImagesCat. No.: HY-18778CCAS No.: 866399-89-5Synonyms: TA-8995 hemicalcium; DEZ-001 hemicalcium; AMG-899 hemicalciumObicetrapib hemicalcium (TA-8995 hemicalcium) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib hemicalcium shifts the plasma lipoprotein profile toward more HDL-C particles, reduces circulating PCSK9 levels, increases hepatic LDLR expression and LDLR mRNA levels, and promotes hepatic clearance of VLDL remnants. Obicetrapib hemicalcium increases the number of large HDL particles, reduces the number and area of atherosclerotic lesions and alleviates lesion severity, increases the proportion of unaffected arterial segments, improves lesion stability, and promotes regression of aortic root lesions. Obicetrapib hemicalcium also exerts a synergistic effect with Ezetimibe (HY-17376) to reduce non-HDL-C levels and improve atherosclerosis. Obicetrapib hemicalcium can be used in studies related to atherosclerosis and dyslipidemia.
-
Evacetrapib (Standard)
0 ImagesCat. No.: HY-13327RCAS No.: 1186486-62-3Synonyms: LY2484595 (Standard)Evacetrapib (Standard) is the analytical standard of Evacetrapib. This product is intended for research and analytical applications. Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
- 1
- 2
